BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15147526)

  • 41. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
    Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
    Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anderson-Fabry disease: developments in diagnosis and treatment.
    Mehta AB
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S66-74. PubMed ID: 20040315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anderson-Fabry disease and the heart.
    O'Mahony C; Elliott P
    Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gastroenterological complications of Anderson-Fabry disease.
    Buda P; Książyk J; Tylki-Szymanska A
    Curr Pharm Des; 2013; 19(33):6009-13. PubMed ID: 23448457
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
    Warnock DG
    J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
    [No Abstract]   [Full Text] [Related]  

  • 46. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
    Barbey F; Widmer U; Burnier M; Lidove O
    Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
    [TBL] [Abstract][Full Text] [Related]  

  • 47. General Anesthesia and Fabry Disease: A Case Report.
    Krüger S; Nowak A; Müller TC
    A A Case Rep; 2017 May; 8(10):247-249. PubMed ID: 28079663
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enzyme replacement therapy and renal function in 201 patients with Fabry disease.
    Schwarting A; Dehout F; Feriozzi S; Beck M; Mehta A; Sunder-Plassmann G;
    Clin Nephrol; 2006 Aug; 66(2):77-84. PubMed ID: 16939062
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.
    Ramaswami U
    Acta Paediatr; 2008 Apr; 97(457):38-40. PubMed ID: 18339186
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fabry disease--a diagnostic and therapeutic problem.
    Strujić BJ; Jeren T
    Ren Fail; 2005; 27(6):783-6. PubMed ID: 16350834
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
    Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
    Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
    Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
    Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Fabry disease: proposed guidelines from a French expert group for its diagnosis, treatment and follow-up].
    Lidove O; Bekri S; Goizet C; Khau Van Kien A; Aractingi S; Knebelmann B; Choukroun G; Tsimaratos M; Redonnet-Vernhet I; Lacombe D; Jaussaud R
    Presse Med; 2007; 36(7-8):1084-97. PubMed ID: 17276649
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A case of Anderson-Fabry disease: a multidisciplinary approach for diagnosis and follow up].
    Zito A; De Pascalis A; Armeni A; Ria P; Barbarini L; Caggiula M; My F; Barbarini S; Trianni G; Napoli M
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234233
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [CME. Fabry disease: rare but not to be missed].
    Steinack C; Gaspert A; Kovacs R; Nowak A
    Praxis (Bern 1994); 2015 Jul; 104(14):719-29. PubMed ID: 26135721
    [No Abstract]   [Full Text] [Related]  

  • 58. Fabry disease in an oligosymptomatic male.
    Altarescu G; Elstein D
    Isr Med Assoc J; 2011 Mar; 13(3):191-2. PubMed ID: 21608346
    [No Abstract]   [Full Text] [Related]  

  • 59. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.
    Whybra C; Kampmann C; Willers I; Davies J; Winchester B; Kriegsmann J; Brühl K; Gal A; Bunge S; Beck M
    J Inherit Metab Dis; 2001 Dec; 24(7):715-24. PubMed ID: 11804208
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fabry Nephropathy.
    Colpart P; Félix S
    Arch Pathol Lab Med; 2017 Aug; 141(8):1127-1131. PubMed ID: 28745569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.